TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-03-06
徐志宏Hsu, Chih-Hung
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
33筆
11
Hung YP, Shao YY, Hsu C, Hsu CH, Lee JM, Yang MH, Chao Y. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. J Formos Med Assoc. 2021 Aug;120(8):1581-1590. doi: 10.1016/j.jfma.2020.11.015. Epub 2020 Dec 15. PMID: 33334658.
12
Shao YY, Lin WY, Lin CP, Lu LC, Hsu CH. Solving the deficit of cancer pain management skills by education programs. Support Care Cancer. 2021 Apr;29(4):1843-1848. doi: 10.1007/s00520-020-05651-2. Epub 2020 Aug 11. PMID: 32779009.
13
Shao YY, Cheng AL, Hsu CH. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2021 May;26(5):422-426. doi: 10.1002/onco.13755. Epub 2021 Mar 20. PMID: 33687750; PMCID: PMC8100545.
14
Huang TC, Liang CW, Li YI, Guo JC, Lin CC, Chen YJ, Cheng AL, Hsu CH. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2021 Aug 25. doi: 10.1007/s00432-021-03772-7. Epub ahead of print. PMID: 34432128.
15
Lin ZZ, Chen BB, Hung YP, Huang PH, Shen YC, Shao YY, Hsu CH, Cheng AL, Lee RC, Chao Y, Hsu C. A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist. 2020 Sep;25(9):e1280-e1285. doi: 10.1634/theoncologist.2020-0143. Epub 2020 Apr 9. PMID: 32271494; PMCID: PMC7485356.
16
Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. Epub 2019 Dec 20. PMID: 32067677.
17
Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2020 Feb;38(1):99-110. doi: 10.1007/s10637-019-00745-z. Epub 2019 Mar 2. PMID: 30825104; PMCID: PMC6985061.
18
Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. PMID: 33026938.
19
Yen CJ, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Nitu IS, Abada P, Hsu Y, Zhu AX, Kang YK. Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer. 2020 Aug;9(4):440-454. doi: 10.1159/000506946. Epub 2020 May 5. PMID: 32999870; PMCID: PMC7506228.
20
Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X. Erratum in: Lancet Oncol. 2020 Jul;21(7):e341. PMID: 32502443.
